High Public-Health Impact in an Influenza-B-Mismatch Season in Southern Italy, 2017-2018.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
05
2019
accepted:
01
08
2019
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Yearly influenza epidemics have considerable effects on public health worldwide. The 2017-2018 influenza season in Italy was of greater severity than previous seasons. The aim of this study was to describe the 2017-2018 influenza season in Southern Italy and the molecular characteristics of the circulating viral strains. The incidence of influenza-like illness (ILI) was analysed. Nasopharyngeal swabs collected from patients with ILI from week 46/2017 to week 17/2018 were tested to identify influenza A viruses (IAV) and influenza B viruses (IBV). Sequencing and phylogenetic analysis of haemagglutinin genes were also performed on 73 positive samples (35 IBV, 36 IAV H1, and 2 IAV H3 strains). During the 2017-2018 season, the peak incidence was 14.32 cases per 1,000 inhabitants. IBV strains were identified in 71.0% of cases. The 35 characterised IBV strains belonged to Yamagata lineage clade 3, the 36 A/H1N1pdm09 strains clustered with the genetic subgroup 6B.1, and the 2 A/H3N2 strains clustered with the genetic subgroup 3C.2a. Intensive-care unit (ICU) admission was required in 50 cases of acute respiratory distress syndrome (ARDS). Among the >64-year age group, 18 out of 26 ICU-ARDS cases (69.2%) were caused by IBV, and 14 of these (77.8%) were B/Yamagata lineage. The 2017-2018 influenza season was one of the most severe in a decade in Southern Italy. IBV mismatch between the trivalent vaccine and the circulating strains occurred. The high number of ICU-ARDS cases caused by B/Yamagata strains in the >64-year age group suggests that further data on the effectiveness of the available influenza vaccines are needed to determine the best way to protect the elderly against both IBV lineages.
Sections du résumé
BACKGROUND
BACKGROUND
Yearly influenza epidemics have considerable effects on public health worldwide. The 2017-2018 influenza season in Italy was of greater severity than previous seasons. The aim of this study was to describe the 2017-2018 influenza season in Southern Italy and the molecular characteristics of the circulating viral strains.
METHODS
METHODS
The incidence of influenza-like illness (ILI) was analysed. Nasopharyngeal swabs collected from patients with ILI from week 46/2017 to week 17/2018 were tested to identify influenza A viruses (IAV) and influenza B viruses (IBV). Sequencing and phylogenetic analysis of haemagglutinin genes were also performed on 73 positive samples (35 IBV, 36 IAV H1, and 2 IAV H3 strains).
RESULTS
RESULTS
During the 2017-2018 season, the peak incidence was 14.32 cases per 1,000 inhabitants. IBV strains were identified in 71.0% of cases. The 35 characterised IBV strains belonged to Yamagata lineage clade 3, the 36 A/H1N1pdm09 strains clustered with the genetic subgroup 6B.1, and the 2 A/H3N2 strains clustered with the genetic subgroup 3C.2a. Intensive-care unit (ICU) admission was required in 50 cases of acute respiratory distress syndrome (ARDS). Among the >64-year age group, 18 out of 26 ICU-ARDS cases (69.2%) were caused by IBV, and 14 of these (77.8%) were B/Yamagata lineage.
CONCLUSIONS
CONCLUSIONS
The 2017-2018 influenza season was one of the most severe in a decade in Southern Italy. IBV mismatch between the trivalent vaccine and the circulating strains occurred. The high number of ICU-ARDS cases caused by B/Yamagata strains in the >64-year age group suggests that further data on the effectiveness of the available influenza vaccines are needed to determine the best way to protect the elderly against both IBV lineages.
Identifiants
pubmed: 31531353
doi: 10.1155/2019/4643260
pmc: PMC6720359
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4643260Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Influenza Other Respir Viruses. 2013 Jul;7(4):546-58
pubmed: 22897919
Influenza Other Respir Viruses. 2015 Sep;9(5):234-46
pubmed: 26031655
J Infect Dis. 2006 Nov 1;194 Suppl 2:S82-91
pubmed: 17163394
Vaccines (Basel). 2018 Mar 08;6(1):
pubmed: 29518013
Vaccine. 2009 Jun 24;27(31):4099-103
pubmed: 19410623
J Prev Med Hyg. 2017 Dec 30;58(4):E279-E287
pubmed: 29707658
Clin Infect Dis. 2019 May 17;68(11):1798-1806
pubmed: 30204854
Emerg Infect Dis. 2010 May;16(5):863-5
pubmed: 20409386
Wkly Epidemiol Rec. 2010 Jan 22;85(4):21-2
pubmed: 20095109
Influenza Other Respir Viruses. 2013 Nov;7(6):1416-26
pubmed: 23927713
Euro Surveill. 2018 Feb;23(7):
pubmed: 29471624
Clin Infect Dis. 2019 May 2;68(10):1754-1757
pubmed: 30312364
Eur J Public Health. 2019 Oct 1;29(5):900-905
pubmed: 30929026
Euro Surveill. 2018 Mar;23(9):
pubmed: 29510782
J Virol. 2008 Mar;82(6):3011-20
pubmed: 18184701
Nature. 2006 Mar 23;440(7083):435-6
pubmed: 16554799
Hum Vaccin Immunother. 2017 Jul 3;13(7):1640-1652
pubmed: 28532276
Hum Vaccin Immunother. 2018 Jun 3;14(6):1331-1341
pubmed: 29425079
Hum Vaccin Immunother. 2018;14(8):1867-1873
pubmed: 29708843
Euro Surveill. 2013 Jan 17;18(3):
pubmed: 23351651